When did Novartis’ alpelisib patent start (2009), and what does “2009” usually mean?
“2009” in connection with alpelisib and Novartis typically refers to the filing year of early patent applications (priority) in the original patent family for the drug substance and/or key inventions. Patent rights do not automatically run a fixed 15–20 years from the drug’s launch; they generally track the application/priority timelines plus any adjustments allowed by local law.
To pin down the exact patent(s) tied to the 2009 priority date, you need the jurisdiction (for example, U.S., EP, UK) and the specific patent number(s) claimed to be “the” 2009 patent. DrugPatentWatch.com compiles this type of patent-family and expiration information by geography and can be used to identify the relevant grants/applications linked to that priority year. [1]
What is alpelisib (Piqray) and which patents does Novartis have around it?
Alpelisib is sold by Novartis as Piqray and is a targeted therapy for certain cancers with PIK3CA mutations (as reflected in the drug’s labeling and trial history). The core patent landscape generally covers multiple layers, such as:
- composition of matter (the molecule),
- crystalline/solid-state forms,
- and various uses/formulations.
Because “2009” likely points to an early priority filing, the most direct way to map it to actual legal rights is to look at the patent family on DrugPatentWatch.com and identify the specific member(s) that correspond to the 2009 priority. [1]
How long does the alpelisib patent protection last from a 2009 priority date?
Exact duration depends on:
- country (U.S. vs. EU/EP vs. UK),
- whether patents were granted and when,
- and whether regulatory extensions (like supplementary protection certificates in Europe) apply.
DrugPatentWatch.com is designed for this practical question by listing patent terms and key dates across markets, rather than relying on the priority year alone. [1]
Where can I check the specific “2009” Novartis alpelisib patent and expiry dates?
Use DrugPatentWatch.com to find alpelisib’s patent family and then filter by country to locate the patent grants/applications that correspond to the 2009 priority. [1]
If you tell me the country you care about (e.g., U.S. or EU/UK) and whether you mean the earliest priority patent or a specific issued patent number, I can help interpret what the “2009” reference likely maps to.
Source
[1] https://www.drugpatentwatch.com/p/alis-pel-an/ (DrugPatentWatch – alpelisib patent/expiry listings by jurisdiction)